Literature DB >> 1712624

Expression of mutant p53, c-erbB-2 and the epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder.

C Wright1, K Mellon, P Johnston, D P Lane, A L Harris, C H Horne, D E Neal.   

Abstract

Expression of the p53, the epidermal growth factor receptor (EGFr; c-erbB-1) and c-erbB-2 proteins was studied in 82 patients with primary transitional cell carcinoma of the bladder using an immuno-histochemical method. Strong or moderate staining was found in 18% of tumours for p53 with weaker staining in a further 36% giving a total of 54% of tumours stained for p53. Strong staining was found in 15% of tumours for c-erbB-2 and in 31% for the EGFr. Tumours invading the bladder muscle were significantly more likely to be strongly stained positively for p53 and/or EGFr compared with superficial tumours: only 15% of invasive tumours were stained negatively for both p53 and EGFr. No statistical association was found between p53 and EGFr expression. Weakly positive associations were found between the expression of c-erbB-2 and p53 and between muscle invasive tumours and increased expression of c-erbB-2. Alterations in the expression of p53, c-erbB-1 and c-erbB-2 were found frequently in human transitional cell carcinoma of the urinary bladder and may be of clinical use in defining patient sub-groups of differing prognosis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1712624      PMCID: PMC1972558          DOI: 10.1038/bjc.1991.211

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  32 in total

1.  T antigen is bound to a host protein in SV40-transformed cells.

Authors:  D P Lane; L V Crawford
Journal:  Nature       Date:  1979-03-15       Impact factor: 49.962

2.  Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation.

Authors:  P Hinds; C Finlay; A J Levine
Journal:  J Virol       Date:  1989-02       Impact factor: 5.103

3.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

Authors:  D J Slamon; W Godolphin; L A Jones; J A Holt; S G Wong; D E Keith; W J Levin; S G Stuart; J Udove; A Ullrich
Journal:  Science       Date:  1989-05-12       Impact factor: 47.728

4.  Mutations in the p53 gene occur in diverse human tumour types.

Authors:  J M Nigro; S J Baker; A C Preisinger; J M Jessup; R Hostetter; K Cleary; S H Bigner; N Davidson; S Baylin; P Devilee
Journal:  Nature       Date:  1989-12-07       Impact factor: 49.962

5.  Genetic alterations during colorectal-tumor development.

Authors:  B Vogelstein; E R Fearon; S R Hamilton; S E Kern; A C Preisinger; M Leppert; Y Nakamura; R White; A M Smits; J L Bos
Journal:  N Engl J Med       Date:  1988-09-01       Impact factor: 91.245

6.  Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer.

Authors:  C Wright; B Angus; S Nicholson; J R Sainsbury; J Cairns; W J Gullick; P Kelly; A L Harris; C H Horne
Journal:  Cancer Res       Date:  1989-04-15       Impact factor: 12.701

7.  Overexpression of the c-erbB-2 oncoprotein in human breast carcinomas: immunohistological assessment correlates with gene amplification.

Authors:  D J Venter; N L Tuzi; S Kumar; W J Gullick
Journal:  Lancet       Date:  1987-07-11       Impact factor: 79.321

8.  Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer.

Authors:  J R Sainsbury; J R Farndon; G K Needham; A J Malcolm; A L Harris
Journal:  Lancet       Date:  1987-06-20       Impact factor: 79.321

9.  Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours.

Authors:  D E Neal; C Marsh; M K Bennett; P D Abel; R R Hall; J R Sainsbury; A L Harris
Journal:  Lancet       Date:  1985-02-16       Impact factor: 79.321

10.  Expression of c-erbB-2 protein product in bladder cancer.

Authors:  C Wright; K Mellon; D E Neal; P Johnston; I P Corbett; C H Horne
Journal:  Br J Cancer       Date:  1990-11       Impact factor: 7.640

View more
  32 in total

1.  erbB2 expression in breast and other human tumours.

Authors:  C Wright; K Prasad; T J Lennard
Journal:  J Clin Pathol       Date:  1992-05       Impact factor: 3.411

2.  Correlation of nuclear p53 over-expression with clinical and histopathological features of transitional cell bladder cancer.

Authors:  Z Sinik; T Alkibay; O Ataoğlu; G Akyol; H Tokuçoğlu; I Bozkirli
Journal:  Int Urol Nephrol       Date:  1997       Impact factor: 2.370

Review 3.  Molecular biology of dissemination in bladder cancer--laboratory findings and clinical significance.

Authors:  B J Schmitz-Dräger; F Jankevicius; R Ackermann
Journal:  World J Urol       Date:  1996       Impact factor: 4.226

Review 4.  Growth factors in bladder cancer.

Authors:  M Liebert
Journal:  World J Urol       Date:  1995       Impact factor: 4.226

Review 5.  Bladder cancer.

Authors:  H Y Leung; T R Griffiths; D E Neal
Journal:  Postgrad Med J       Date:  1996-12       Impact factor: 2.401

Review 6.  Molecular substratification of bladder cancer: moving towards individualized patient management.

Authors:  Anirban P Mitra
Journal:  Ther Adv Urol       Date:  2016-03-28

7.  Small-cell carcinoma of the urinary bladder. A clinico-pathological study of ten cases.

Authors:  P Soriano; S Navarro; M Gil; A Llombart-Bosch
Journal:  Virchows Arch       Date:  2004-07-10       Impact factor: 4.064

Review 8.  Superficial bladder cancer.

Authors:  R R Hall
Journal:  BMJ       Date:  1994-04-02

9.  Physical deletion of the p53 gene in bladder cancer. Detection by fluorescence in situ hybridization.

Authors:  G Sauter; G Deng; H Moch; R Kerschmann; K Matsumura; S De Vries; T George; J Fuentes; P Carroll; M J Mihatsch
Journal:  Am J Pathol       Date:  1994-04       Impact factor: 4.307

10.  Utility of a dual immunostain cocktail comprising of p53 and CK20 to aid in the diagnosis of non-neoplastic and neoplastic bladder biopsies.

Authors:  Isil Z Yildiz; Rosemary Recavarren; Henry B Armah; Sheldon Bastacky; Rajiv Dhir; Anil V Parwani
Journal:  Diagn Pathol       Date:  2009-10-14       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.